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Abstract
In breast cancer patients submitted to neoadjuvant chemotherapy (4 cycles of doxorubicin and cyclophosphamide, AC), expres-
sion of groups of three genes (gene trio signatures) could distinguish responsive from non-responsive tumors, as demonstrated 
by cDNA microarray profiling in a previous study by our group. In the current study, we determined if the expression of the same 
genes would retain the predictive strength, when analyzed by a more accessible technique (real-time RT-PCR). We evaluated 28 
samples already analyzed by cDNA microarray, as a technical validation procedure, and 14 tumors, as an independent biological 
validation set. All patients received neoadjuvant chemotherapy (4 AC). Among five trio combinations previously identified, defined 
by nine genes individually investigated (BZRP, CLPTM1, MTSS1, NOTCH1, NUP210, PRSS11, RPL37A, SMYD2, and XLHSRF-1), 
the most accurate were established by RPL37A, XLHSRF-1 based trios, with NOTCH1 or NUP210. Both trios correctly separated 
86% of tumors (87% sensitivity and 80% specificity for predicting response), according to their response to chemotherapy (82% 
in a leave-one-out cross-validation method). Using the pre-established features obtained by linear discriminant analysis, 71% 
samples from the biological validation set were also correctly classified by both trios (72% sensitivity; 66% specificity). Further-
more, we explored other gene combinations to achieve a higher accuracy in the technical validation group (as a training set). A 
new trio, MTSS1, RPL37 and SMYD2, correctly classified 93% of samples from the technical validation group (95% sensitivity 
and 80% specificity; 86% accuracy by the cross-validation method) and 79% from the biological validation group (72% sensitivity 
and 100% specificity). Therefore, the combined expression of MTSS1, RPL37 and SMYD2, as evaluated by real-time RT-PCR, 
is a potential candidate to predict response to neoadjuvant doxorubicin and cyclophosphamide in breast cancer patients.
Key words: Breast neoplasms; Discriminant analysis; Doxorubicin; Drug resistance; Neoadjuvant therapy; Reverse transcriptase-
polymerase chain reaction 
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A major benefit of primary chemotherapy in breast 
cancer is the opportunity to increase breast-conserving 
surgery rates (1,2). However, for a more precise indication 
of this treatment, it is crucial to identify responsive and 
non-responsive patients. In this ideal situation, responsive 
patients, who might present a reduction in tumor dimen-
sion, would be offered primary chemotherapy, while non-
responsive patients, who might present stable or progressive 
disease, would be offered breast surgery at once.
Much work has been done in order to identify predictive 
markers of tumor response to primary chemotherapy and 
proliferation index, tumor grade, expression of hormone 
receptors and HER2, among others (3,4), all seem to play 
a role. In addition, basal-like and HER2(+)/ER(-) subtypes 
are more sensitive to anthracycline-based neoadjuvant 
chemotherapy than luminal breast cancers (4).
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Moreover, many studies have been carried out to iden-
tify a gene expression profile predictive of drug response 
in breast cancer patients employing cDNA microarray (5-
10) or RT-PCR techniques (11). Most investigators have 
tried to detect expression profiles associated with patho-
logical complete response (7-9,11), which is a surrogate 
marker for improved overall survival. Others, however, 
have searched for expression profiles related to clinical 
response (5,6,10), which allow identification of patients 
who may benefit from tumor reduction and enhanced pos-
sibility of breast-conserving surgery. Differential expression 
profiles have been identified, and the response to various 
regimens, based on anthracycline (5,8), taxanes (6) or 
both drugs (7,9-11), has been analyzed. Some of these 
studies included samples only in a training group (8,10), 
while others assessed the reproducibility of the model in 
an independent group of patients, regardless of the use of 
cross-validation analysis (5,6,9,11). In common, these stud-
ies have employed the same technique (cDNA microarray 
or RT-PCR) to detect gene expression in both the training 
and validation groups.
We have identified predictive markers of the response 
to neoadjuvant chemotherapy based on doxorubicin (5). 
Forty-four breast cancer patients submitted to neoadjuvant 
chemotherapy (AC) had tumor samples collected before 
treatment and their response was evaluated according to 
RECIST criteria. Tumor gene expression was evaluated by 
cDNA microarray and after an extensive search, 10 groups 
of three genes (gene trio signatures) were identified, which 
could separate responsive from non-responsive tumors 
with high accuracy (spread error ≤0.05): PRSS11/CLPTM1/
MTSS1; PRSS11/SMYD2/MTSS1; XLHSRF-1/NOTCH1/
RPL37A; PRSS11/BZRP/MTSS1; XLHSRF-1/NUP210/
RPL37A; XLHSRF-1/NCKAP1/PHLDA3; AP3M1/PRSS11/
MTSS1; PRSS11/VAPB/MTSS1; XLHSRF-1/RPL37A/
TPM1; PRSS11/GCC1/MTSS1. Expression of one of these 
trios (PRSS11, CLPTM1, MTSS1) could properly group all 
the 31 samples of the training set with 100% correct clas-
sification upon the leave-one-out cross-validation, which is 
a procedure to test the validity of class predictors (5-8). In 
addition, this trio could correctly classify 84.6% of the 13 
samples from the validation set (91% sensitivity and 50% 
specificity to predict tumor response) (5).
Our objective was to determine whether expression of 
some of these trios of genes, as evaluated by real-time RT-
PCR, which is a more accessible mRNA identification and 
quantification technique, would retain its predictive strength 
to separate tumors according to response to primary che-
motherapy based on doxorubicin and cyclophosphamide.
Patients and Methods
Patients
The study was approved by the local Ethics Committee 
of the Instituto Brasileiro de Controle do Câncer and Hospital 
das Clínicas da Faculdade de Medicina da USP, São Paulo, 
and breast cancer patients, candidates for neoadjuvant 
chemotherapy on a routine basis, gave written informed 
consent to participate.
Twenty-eight patients whose samples had been studied 
by cDNA microarray in a previous study (5) had enough 
material available for the determination of gene expression 
by real-time RT-PCR and their samples were included in 
a technical validation group. Another 14 patients were 
prospectively accrued, and their tumors were analyzed in 
a biological validation group (Table 1).
Patients included in the technical and biological valida-
tion groups presented mainly a locally advanced disease 
and were treated with 4 cycles of neoadjuvant doxorubicin 
and cyclophosphamide. There were no differences between 
groups, except for estrogen receptor immuno-expression, 
which was detected in a higher proportion of tumors from 
the technical validation group (Table 1).
Breast tumor dimension was evaluated by clinical 
examination before the first cycle and approximately three 
weeks after the last cycle of chemotherapy. Responsive 
patients were those whose tumor achieved a reduction of 
at least 30% of the longest diameter of the primary tumor 
(Table 1). Around 80% of patients from both technical and 
biological validation groups presented at least a partial 
response (Table 1). No association was detected between 
response to chemotherapy and menopausal status, clini-
cal stage, histological type, histological grade, hormone 
receptor status, HER2 and P53 immuno-expression (data 
not shown).
RNA extraction, reverse transcription and real-time PCR
Tumor samples collected before chemotherapy were 
examined by light microscopy and hand dissected if neces-
sary, to guarantee the presence of at least 80% invasive 
tumor cells. Total RNA was isolated using Trizol reagent 
(Invitrogen Corporation, USA). RNA quality was determined 
by ratio of absorbance at 260 and 280 nm (higher than 1.6) 
and by 28S/18S rRNA band intensities, as verified by 1% 
agarose gel electrophoresis under denaturing conditions 
and visualization through ethidium bromide (>1.5 ratio).
Total RNA (2 µg) was reverse transcribed using the 
oligo dT12-18 primer (GE Healthcare Life Sciences, UK) 
and Superscript III (Invitrogen Corporation). Real-time RT-
PCR was carried out using SYBR-green I (Sigma, USA) in 
a Rotor-gene system (Corbett Research, Australia). Primer 
sets were designed based on a coding region closer to the 
3’ end of the gene, using Primer3 (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi) (Table 2). Sequences 
present in different exons, preferentially separated by long 
introns, were selected according to sequences deposited at 
http://www.ncbi.nlm.nih.gov/nucleotide. To avoid nonspe-
cific product formation, BLAST alignment analysis (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) was carried out.
All samples were analyzed in duplicate and cycling con-
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ditions were 95°C for 5 min, followed by 40 cycles at 95°C 
for 20 s, 60°C for 15 s and 72°C for 20 s. PCR assays were 
analyzed with the Rotor-Gene 6 System software (Corbett 
Research). Average values were used for quantification 
and cDNA obtained from a pool of breast samples was 
used as reference. 
Reference gene selection and real-time RT-PCR 
normalization
Expression stability of four housekeeping genes, in-
cluding ACTB (actin, beta), GUSB (glucuronidase, beta), 
PPIA [peptidylprolyl isomerase A (cyclophilin A)], and 
RPLP0 (ribosomal protein, large, P0) was determined in 
target samples using the geNorm software tool (available at 
http://medgen.ugent.be/~jvdesomp/genorm/). All candidate 
genes presented an M value below the 1.5 cut-off, indicat-
ing a small variability of their expression among samples. 
ACTB, PPIA and RPLP0 presented similar expression in 
responsive and non-responsive samples, whereas GUSB 
was significantly less expressed in non-responsive samples 
(P = 0.006, Mann-Whitney test), being excluded as a refer-
ence gene from this analysis (data not shown).
The relative normalized expression ratio was calculated 
from the real-time PCR efficiency and the crossing point de-
viation of an unknown sample versus a control divided by the 
normalization factor, which was the geometric mean of the 
relative expression values of ACTB, PPIA and RPLP0.
Statistical analysis
Statistical analysis was performed using the SPSS 11.0 
version software (SPSS, USA). Relative normalized expres-
sion data were first transformed to their natural logarithm (ln) 
format and the Shapiro-Wilk test was performed to determine 
the distribution of the values. The results obtained by cDNA 
microarray and real-time RT-PCR were then compared us-
ing the Spearman or Pearson correlation test, as appropri-
ate. The level of significance of the differential expression 
between responsive and non-responsive samples was 
determined by the Mann-Whitney test and a two sided P ≤ 
0.05 value was considered to be significant.
Predictive models using gene expression values were 
designed using linear discriminant analysis. Gene sets 
showing greater accuracy in leave-one-out cross-validation 
analysis were further tested with samples from the biologi-
cal validation group.
Results
We first determined whether there was a correlation 
between the mRNA quantification techniques (cDNA mi-
croarray vs real-time RT-PCR) for the expression values of 
all nine genes studied. Samples from the technical validation 
group (N = 28) were used in this analysis, as their gene 
expression had already been evaluated by cDNA microarray. 
A significant positive correlation between values was found 
Table 1. Patient characteristics and response to neoadjuvant chemotherapy.
Characteristics Technical validation 
group (N = 28)
Biological validation
group (N = 14)
P
Median age (years, min-max) 50 (32-67) 54 (27-70) 0.680a
Postmenopausal 50% (13/26) 69% (9/13) 0.254#
Clinical stage III 75% (21/28) 71% (10/14) 1.000*
Breast lesion dimension (mm) (mean; min-max) 72 (20-300) 81 (40-150) 0.250b
IDC 82% (23/28) 79% (11/14) 1.000*
HG 3 22% (6/27) 36% (4/11) 0.432*
ER(+) 79% (22/28) 43% (6/14) 0.036*
PR(+) 50% (14/28) 43% (6/14) 0.690#
HER2(+) 19% (5/27) 36% (5/14) 0.267*
p53(+) 46% (11/24) 42% (5/12) 0.473#
LN(+) 64% (16/25) 38% (5/13) 0.133#
Median chemotherapy duration 70 days 72 days
Mean dose administered 97% 97%
Clinical responsec 1.000*
Complete or partial 82% 79%
Stable/progressive disease 18% 21%
IDC = invasive ductal carcinoma; HG 3 = histological grade 3; (+) positive; ER = estrogen receptor; PR = pro-
gesterone receptor; HER2 = HER2 over-expression; p53 = p53 immunoexpression; LN = lymph node involve-
ment. *Fisher exact test; #Pearson chi-square. The Kolmogorov-Smirnov test was applied followed by at-test 
for parametric data or bMann-Whitney test for non-parametric data. cClinical response determined according to 
Therasse et al. J Natl Cancer Inst 2000; 92: 205-216. 
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for NUP210 (nucleoporin 210 kDa; r = 0.484; P = 0.009), 
PRSS11 [protease, serine, 11 (IGF binding); r = 0.408; P 
= 0.031], RPL37A [(ribosomal protein L37a); r = 0.505; P = 
0.033], SMYD2 [(SET and MYND domain containing 2); r 
= 0.434; P = 0.021], and a trend towards a correlation was 
found for MTSS1 [(mammalian metastasis suppressor 1); r 
= 0.360; P = 0.060] expression values (Pearson or Spear-
man correlation test, as appropriate). Although there was 
no correlation between the two methods for the expression 
of BZRP (peripheral benzodiazepine receptor), CLPTM1 
(cleft lip and palate-associated transmembrane protein-1), 
NOTCH1 [Notch homolog 1, translocation-associated (Dros-
ophila)], XLHSRF-1 (heat shock regulated 1), no significant 
negative correlation was detected. Among the correlated 
genes, RPL37A was the only one with significant differential 
expression in both techniques for the same 28 samples, 
indicating lower expression in non-responsive than in re-
sponsive tumors (cDNA microarray, P = 0.021 vs RT-PCR, 
P = 0.011; Mann-Whitney test).
Our next step was to examine whether real-time RT-PCR 
expression values from these nine genes grouped into trios 
could provide results similar to those obtained by cDNA 
microarray in separating responsive from non-responsive tu-
mors, using linear discriminant analysis. Initially, we evaluated 
the three-dimensional distribution of tumors according to the 
expression of five gene trios previously identified. Samples 
from the technical validation group were used to generate 
the best separation plane to discriminate responsive from 
non-responsive tumors. Among the five trios, the best sepa-
ration of tumors was achieved by the RPL37A, XLHSRF-1 
based trios (with NOTCH1 or NUP210, as third genes), which 
could correctly classify 86% (21/23 responsive) and 60% 
(3/5 non-responsive) of the technical validation group. In a 
cross-validation analysis (leave-one-out) 82% of samples 
maintained the adequate separation considering both gene 
trios (20/23 responsive and 3/5 non-responsive). Conversely, 
the other three trios presented less than 50% correct sample 
discrimination in cross-validation analysis. Next, samples from 
the biological validation group were spatially distributed using 
the pre-established features from these two trios, resulting 
in a 71% (8/11 responsive and 2/3 non-responsive) correct 
classification by both of them (Figure 1A and B). 
Table 2. List of primers.
Gene symbol GenBank accession number Primer sequences Amplicon size (bp)
ACTB* NM_001101 S - 5’ AGAAAATCTGGCACCAACC 3’ 188
AS - 5’ AGAGGCGTACAGGGATAGCA 3’
GUSB* NM_000181 S - 5’ GGTTGGAGAGCTCATTTGGA 3’ 160
AS - 5’ CCTGGTTTCATTGGCAATCT 3’
PPIA* NM_021130 S - 5’ CAAATGCTGGACCCAACACA 3’ 170
AS - 5’ TGCCATCCAACCACTCAGTC 3’
RPLP0* NM_001002 S - 5’ GGCGACCTGGAAGTCCAACT 3’ 149
AS - 5’ CCATCAGCACCACAGCCTTC 3’
BZRP NM_000714 S - 5’ GCCATACGCAGTAGTTGAG 3’ 173
AS - 5’ CTTCTTTGGTGCCCGACA 3’
CLPTM1 NM_001294 S - 5’ GATGACAAAGGCGAACAGGT 3’ 153
AS - 5’ CTCTACGGCTTCCTGCTGAC 3’
MTSS1 NM_014751 S - 5’ CTACAGCACCCAGACAACCA 3’ 286
AS - 5’ GACAGAAGGCTTGGTGGAAG 3’
NOTCH1 NM_017617 S - 5’ CATATGATCCGTGATGTCC 3’ 149
AS - 5’ CAGTTGTGCTCCTGAAGAA 3’
NUP210 NM_024923 S - 5’ GGGCTTGTTCCAGTGTGAAT 3’ 199
AS - 5’ CCACTATTTCGCTGCCTCAT 3’
PRSS11 NM_002775 S - 5’ GGACTGTCCATTGATGCTGA 3’ 115
AS - 5’ GGACTTCCCAGACGTGATCT 3’
RPL37A NM_000998 S - 5’ TTCTGATGGCGGACTTTACC 3’  95
AS - 5’ GATCTGGCACTGTGGTTCCT 3’
SMYD2 NM_020197 S - 5’ TCAGTGGCTTTCAATTTCCTG 3’ 155
AS - 5’ CCATGTGGTTGAAGCTAGGG 3’
XLHSRF-1 NM_015512 S - 5’ GCTGGGAAAACTGGTTGATG 3’ 171
AS - 5’ TCTACGACAGCTGGGTCAAG 3’
S = sense; AS = antisense.
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Figure 1. A, Three-dimensional distribution of samples from technical and biological validation groups according to the expression of 
gene trios. A, RPL37A, XLHSRF-1, NOTCH1. B, RPL37A, XLHSRF-1, NUP210. C and D, RPL37A, SMYD2, MTSS1. A, B, C, D, The 
expression of gene trios was evaluated in samples from a technical validation group (N = 28, circles) and biological validation group 
(N = 14, crosses). Expression values from samples of the technical validation (training) group were first used to generate a separation 
plane (green line) between responsive (green) and non-responsive tumors (red), using linear discriminant analysis. Then, samples of 
the biological validation group were spatially distributed according to these pre-established features to determine the accuracy of the 
model. A and B, Gene trios previously identified in cDNA microarray analysis had their expression now evaluated by RT-PCR and these 
results are shown as their natural logarithm values. C and D, Gene trio newly identified by RT-PCR analysis. C, Expression values, 
as evaluated by RT-PCR, are shown for samples of the technical (N = 28) and biological validation groups (N = 14). D, Expression 
values evaluated by cDNA microarray experiments are shown for the technical validation group (N = 28) and for another 16 samples 
from patients submitted to neoadjuvant chemotherapy, who had their tumors analyzed only by cDNA microarray, and who constituted 
another biological validation group. Gene names shown on the axis indicate increasing values of gene expression.
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Since neither of these trios could discriminate samples 
with the same accuracy as in previous cDNA microarray 
analysis, we decided to search for other predictive trios, 
combining the real-time RT-PCR expression values of 
genes with at least a trend towards a positive correlation 
between techniques (MTSS1, NUP210, PRSS11, RPL37A, 
and SMYD2). Expression of RPL37A, SMYD2 and MTSS1 
presented the highest accuracy, correctly separating 93% of 
the technical validation group samples (22/23 responsive; 
4/5 non-responsive) and 86% accuracy by cross-validation 
analysis (21/23 responsive and 3/5 non-responsive). This 
trio was further tested using samples from the biological 
validation group, which were spatially distributed using the 
pre-established features, resulting in 79% proper classifica-
tion (8/11 responsive and 3/3 non-responsive) (Figure 1C). 
Hence, this predictive model presented 72% sensitivity, 
100% specificity, and positive and negative predictive values 
of 100 and 50%, respectively, in discriminating responsive 
tumors from an independent sample group.
As this newly identified trio was not one of the top 10 
trios detected by cDNA microarray analysis, we re-evaluated 
its strength in separating responsive from non-responsive 
samples from all 44 patients included in our previous study 
(5). cDNA microarray expression for the 28 patients included 
in the technical validation group (who had samples analyzed 
by both cDNA microarray and RT-PCR) was used to delin-
eate a separating plane, which correctly classified 89% of 
the samples (21/23 responsive and 4/5 non-responsive). 
Cross-validation analysis also demonstrated 86% accu-
racy (20/23 responsive and 4/5 non-responsive). Thus, 
using the same samples and gene expression evaluated 
by cDNA microarray, four samples were erroneously clas-
sified. However, only two of them were misclassified by 
both RT-PCR and cDNA microarray analysis (one of them 
responsive and the other non-responsive). The remain-
ing 16 samples of the 44 included in our previous study, 
which were analyzed only by cDNA microarray (there was 
not enough material available for RT-PCR analysis), were 
later included as another validation group. The median age 
of this group of patients was 46 years, 94% had invasive 
ductal carcinoma (75% ER+, 69% PR+ and 56% ErbB2+), 
clinical stage III disease (mean dimension of the primary 
tumor before chemotherapy: 82 mm), and 75% of them 
were considered to be responsive after treatment. In this 
new biological validation group of 16 patients, 81% of the 
samples were properly separated (11/12 responsive and 
2/4 non-responsive) (Figure 1D). This model presented 
92% sensitivity, 50% specificity, and positive and negative 
predictive values of 85 and 67%, respectively, in discrimi-
nating responsive tumors.
Discussion
We have performed a more comprehensive analysis 
of tumor gene expression profile using cDNA microarray, 
in which ten trios of genes presented high accuracy in dis-
criminating samples according to drug response (5). We 
have determined whether expression of some of these trios 
could predict the response of canine mammary carcinomas 
using an in vitro tissue slice culture and RT-PCR assay. In 
this model, however, they could not predict in vitro respon-
siveness to doxorubicin. In this case, inter-species genetic 
heterogeneity may have contributed to determining a diverse 
gene expression associated with tumor response (12).
In the present study, we observed that expression of the 
same trios of genes previously identified and now evaluated 
by real-time RT-PCR did not provide predictive informa-
tion with the same accuracy as that obtained with cDNA 
microarray data, even when the same 28 samples (of 44) 
previously analyzed were used. This can be explained in 
part by the fact that only one among the five trios included 
all three genes (PRSS11, SMYD2 and MTSS1) with at 
least a trend towards a positive correlation, considering the 
expression values obtained by the two techniques (cDNA 
microarray and real-time RT-PCR).
This difficulty in reproducing gene expression profiles 
identified by cDNA microarray and real-time RT-PCR meth-
odology has been reported by other investigators and a wide 
range of validation rates, represented by significant positive 
correlations between the techniques, was detected (34-
71%) (5,6,13-16). This can be explained by disparieties in 
technical principles and normalization approaches between 
these two methods. Microarray data are frequently normal-
ized globally, and therefore the expression levels of all genes 
are assumed to be constant among samples. Conversely, 
RT-PCR expression data are normalized by a much smaller 
number of reference genes (e.g., often only one), assumed 
to be constant, despite the fact that no single gene is ex-
pressed at a constant level in all biological samples. Based 
on these observations, we took extreme care in choosing 
reference genes for RT-PCR in order to select those with 
stable expression among all cancer samples and between 
groups (response vs non-response).
Using RT-PCR expression values of the pre-selected 
genes, we identified the RPL37A, SMYD2 and MTSS1 trio 
as a new, potential predictive marker. This discriminating 
power could represent the sum of effect of these three genes 
within the process of response to chemotherapy response. 
A higher expression of RPL37A and MTSS1 and a lower 
expression of SMYD2 contributed to graphic localization 
of responsive compared to non-responsive samples, using 
both procedures (cDNA microarray and RT-PCR). RPL37A 
encodes a ribosomal protein that is a component of the 60S 
subunit. In agreement with our data, higher expression of 
structural constituents of ribosomes was described in breast 
cancer specimens responsive to letrozole in the neoadjuvant 
setting (17). SMYD2 may repress transcriptional p53 activity 
by lysine methylation (Lys172), exerting an oncogenic and 
drug resistance action through inhibition of p53-mediated 
cell death pathways (18). MTSS1 codes for a metastasis 
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suppressor protein and participates in the assembly of actin 
filaments. Its negative regulation correlates with prolifera-
tion, adhesion loss and invasion and a higher breast tumor 
expression of MTSS1 was correlated with increased patient 
overall survival and disease-free survival (19).
Although the RPL37A, SMYD2, MTSS1 trio does not 
overlap with other identified predictive gene expression pro-
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can distinguish specific tumor behaviors (20).
In conclusion, expression of the RPL37A, SMYD2, 
MTSS1 gene trio, as evaluated by RT-PCR, is a potential 
candidate for a predictive marker of response to neoadjuvant 
AC chemotherapy in breast cancer patients.
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